Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Coya Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
COYA
Nasdaq
8731
https://www.coyatherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Coya Therapeutics Inc
We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate
- Mar 27th, 2024 12:37 pm
Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates
- Mar 21st, 2024 9:31 am
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
- Mar 19th, 2024 12:15 pm
Coya Therapeutics to Participate in BTIG Fireside Discussion
- Mar 12th, 2024 1:00 pm
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
- Mar 12th, 2024 12:00 pm
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
- Mar 6th, 2024 1:15 pm
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
- Feb 29th, 2024 1:15 pm
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
- Feb 22nd, 2024 1:15 pm
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"
- Feb 21st, 2024 1:15 pm
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
- Feb 13th, 2024 1:15 pm
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
- Jan 29th, 2024 1:15 pm
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
- Jan 18th, 2024 1:15 pm
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
- Jan 16th, 2024 1:15 pm
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
- Jan 16th, 2024 8:59 am
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Jan 5th, 2024 1:00 pm
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
- Dec 20th, 2023 1:30 pm
David Einhorn's Greenlight Capital Adds Coya Therapeutics to Its Portfolio
- Dec 14th, 2023 8:54 pm
David Einhorn's Greenlight Capital Boosts Coya Therapeutics Holding
- Dec 14th, 2023 8:54 pm
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
- Dec 13th, 2023 1:00 pm
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
- Dec 12th, 2023 1:00 pm
Scroll